Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 34Active not recruiting 23Completed 7Not yet recruiting 4Suspended 2Available 2Terminated 1No longer available 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2CNS 1

Conditions

Leukemia, Myeloid, Acute 10Breast Neoplasms 9Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Neoplasm Metastasis 7Lung Neoplasms 6Glioblastoma 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Hematologic Neoplasms 5Colorectal Neoplasms 5Carcinoma, Hepatocellular 5Ovarian Neoplasms 4Myelodysplastic Syndromes 4Multiple Myeloma 4Carcinoma, Renal Cell 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Sarcoma 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Melanoma 3Head and Neck Neoplasms 3Urinary Bladder Neoplasms 2Solid Tumor 2Recurrence 2Rectal Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Osteosarcoma 2Neoplasm, Residual 2NSCLC 2

Interventions

Specimen Handling 2trastuzumab deruxtecan 1fludarabine phosphate 1X-Rays 1Cyclophosphamide 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Suspended × Osteosarcoma × 90 days × Clear all
NCT04539366 2026-05-13

Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial

National Cancer Institute (NCI)

Phase 1 Suspended
67 enrolled
CNSSarcoma

Neuroblastoma, Osteosarcoma

NCT04616560 2026-05-13

Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma

National Cancer Institute (NCI)

Phase 2 Suspended
77 enrolled
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡